Azenta UK Ltd., a wholly owned subsidiary of Azenta, Inc., entered into a Share Purchase Agreement on March 4, 2026, to acquire all issued and outstanding share capital of UK Biocentre Limited for total consideration of GBP 20.5 million net of cash, inclusive of up to GBP 1.8 million in contingent consideration. UK Biocentre will serve as a European-wide hub for Azenta’s Sample Repository Services business and continue operating under its name.
Key takeaways
Azenta UK Ltd. acquired 100% of UK Biocentre Limited's share capital on March 4, 2026
Total consideration: GBP 20.5 million net of cash + up to GBP 1.8 million contingent consideration
UK Biocentre provides sample management, storage, and high-throughput sample processing services in the UK
UK Biocentre generated GBP 15.3 million revenue for twelve months ending September 30, 2025
Acquisition establishes UK Biocentre as European hub for Azenta’s Sample Repository Services
Press release furnished as Exhibit 99.1; Share Purchase Agreement filed as Exhibit 2.1